Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration

Author(s): Viviana Frantellizzi*, Mariano Pontico, Arianna Pani, Roberto Pani, Giuseppe De Vincentis

Journal Name: Current Radiopharmaceuticals

Volume 13 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: To our knowledge, no previous study or literature review has been performed about the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences, especially regarding alpha-particle emitting radiopharmaceuticals.

Methods: Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the correctness of the procedures applied , unexpected delayed adverse effects can occur.

In our vast experience, we rarely observed lymphedema, even after some time, at the site of administration.

Results: Management of lymphedema caused by radiopharmaceuticals administration has been addressed through clinical examples. The sudden intervention allowed a fast remission of the signs and symptoms complained by patients treated with Radium-223 dichloride.

Conclusion: The management of adverse effects after radiopharmaceuticals administration as in case of lymphedema onset, is extremely simple. These data confirm the safety of Radium-223 treatment.

Keywords: Ra-223 dichloride, alpha particle therapy, lymphedema, life quality, radiopharmaceutical adverse effects.

[1]
Laroche, M.L.; Quelven, I.; Mazère, J.; Merle, L. Adverse reactions to radiopharmaceuticals in France: Analysis of the national pharmacovigilance database. Ann. Pharmacother., 2015, 49(1), 39-47.
[http://dx.doi.org/10.1177/1060028014558153] [PMID: 25366341]
[2]
Sciarra, A.; Gentilucci, A.; Salciccia, S.; Von Heland, M.; Ricciuti, G.P.; Marzio, V.; Pierella, F.; Musio, D.; Tombolini, V.; Frantellizzi, V.; Pasquini, M.; Maraone, A.; Guandalini, A.; Maggi, M. Psychological and functional effect of different primary treatments for prostate cancer: A comparative prospective analysis. Urol. Oncol., 2018, 36(7), 340.e7-340.e21.
[http://dx.doi.org/10.1016/j.urolonc.2018.03.022] [PMID: 29706458]
[3]
Ricci, M.; Frantellizzi, V.; Bulzonetti, N.; De Vincentis, G. Reversibility of castration resistance status after Radium-223 dichloride treatment: Clinical evidence and Review of the literature. Int. J. Radiat. Biol., 2018, 1-29.
[PMID: 30557063]
[4]
Du, Y.; Carrio, I.; De Vincentis, G.; Fanti, S.; Ilhan, H.; Mommsen, C.; Nitzsche, E.; Sundram, F.; Vogel, W.; Oyen, W.; Lewington, V. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(10), 1671-1678.
[http://dx.doi.org/10.1007/s00259-017-3756-7] [PMID: 28631036]
[5]
Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S.I.; O’Sullivan, J.M.; Fosså, S.D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; Widmark, A.; Johannessen, D.C.; Hoskin, P.; Bottomley, D.; James, N.D.; Solberg, A.; Syndikus, I.; Kliment, J.; Wedel, S.; Boehmer, S.; Dall’Oglio, M.; Franzén, L.; Coleman, R.; Vogelzang, N.J.; O’Bryan-Tear, C.G.; Staudacher, K.; Garcia-Vargas, J.; Shan, M.; Bruland, Ø.S.; Sartor, O. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med., 2013, 369(3), 213-223.
[http://dx.doi.org/10.1056/NEJMoa1213755] [PMID: 23863050]
[6]
De Vincentis, G.; Monari, F.; Baldari, S.; Salgarello, M.; Frantellizzi, V.; Salvi, E.; Reale, L.; Napolitano, S.; Conti, G.; Cortesi, E. Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care. Future Oncol., 2018, 14(27), 2821-2832.
[http://dx.doi.org/10.2217/fon-2018-0318] [PMID: 29905090]
[7]
Frantellizzi, V.; Farcomeni, A.; Follacchio, G.A.; Pacilio, M.; Pellegrini, R.; Pani, R.; De Vincentis, G. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride. Ann. Nucl. Med., 2018, 32(2), 142-148.
[http://dx.doi.org/10.1007/s12149-017-1228-6] [PMID: 29285670]
[8]
De Vincentis, G.; Follacchio, G.A.; Frantellizzi, V.; Prelaj, A.; Farcomeni, A.; Giuli, A.; Bianco, V.; Tomao, S. 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. Aging Clin. Exp. Res., 2018, 30(6), 677-680.
[http://dx.doi.org/10.1007/s40520-017-0826-4] [PMID: 28856577]
[9]
Coleman, R.; Aksnes, A-K.; Naume, B.; Garcia, C.; Jerusalem, G.; Piccart, M.; Vobecky, N.; Thuresson, M.; Flamen, P. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res. Treat., 2014, 145(2), 411-418.
[http://dx.doi.org/10.1007/s10549-014-2939-1] [PMID: 24728613]
[10]
Kennedy-Dixon, T.G.; Gossell-Williams, M.; Cooper, M.; Trabelsi, M.; Vinjamuri, S. Evaluation of radiopharmaceutical adverse reaction reports to the british nuclear medicine society from 2007 to 2016. J. Nucl. Med., 2017, 58(12), 2010-2012.
[http://dx.doi.org/10.2967/jnumed.117.194092] [PMID: 28522742]
[11]
Salvatori, M.; Treglia, G.; Mores, N. Further considerations on adverse reactions to radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(8), 1360-1362.
[http://dx.doi.org/10.1007/s00259-012-2120-1] [PMID: 22526962]
[12]
van der Pol, J.; Vöö, S.; Bucerius, J.; Mottaghy, F.M. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(7), 1234-1243.
[http://dx.doi.org/10.1007/s00259-017-3675-7] [PMID: 28303300]
[13]
Hesse, B.; Vinberg, N.; Berthelsen, A.K.; Ballinger, J.R. Adverse events in nuclear medicine - cause for concern? Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(5), 782-785.
[http://dx.doi.org/10.1007/s00259-012-2071-6] [PMID: 22310855]
[14]
Tennvall, J.; Fischer, M.; Bischof Delaloye, A.; Bombardieri, E.; Bodei, L.; Giammarile, F.; Lassmann, M.; Oyen, W.; Brans, B. Therapy committee. EANM oncology committee, EANM dosimetry committee, EANM. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(4), 616-622.
[http://dx.doi.org/10.1007/s00259-007-0372-y] [PMID: 17323056]
[15]
Fu, M.R.; Ridner, S.H.; Hu, S.H.; Stewart, B.R.; Cormier, J.N.; Armer, J.M. Psychosocial impact of lymphedema: A systematic review of literature from 2004 to 2011. Psychooncology, 2013, 22(7), 1466-1484.
[http://dx.doi.org/10.1002/pon.3201] [PMID: 23044512]
[16]
Fu, M.R.; Axelrod, D.; Haber, J. Breast-cancer-related lymphedema: information, symptoms, and risk-reduction behaviors. J. Nurs. Scholarsh., 2008, 40(4), 341-348.
[http://dx.doi.org/10.1111/j.1547-5069.2008.00248.x] [PMID: 19094149]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 2
Year: 2020
Page: [159 - 163]
Pages: 5
DOI: 10.2174/1874471012666190927115331

Article Metrics

PDF: 26
HTML: 1